SPAC Mergers Are Viable Funding Tools, But The Test Is Yet To Come
Performance Has Been Subpar For Most That Have Taken SPAC Route
Dozens of health care-focused special purpose acquisition corporations have gone public during the past two years but many biopharma firms that have merged with SPACs have not performed well to date, raising the question of how long the SPAC boom will last.
